HighVista Strategies LLC Has $1.15 Million Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

HighVista Strategies LLC lessened its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 29.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,852 shares of the company's stock after selling 15,135 shares during the period. HighVista Strategies LLC's holdings in SpringWorks Therapeutics were worth $1,149,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co lifted its stake in SpringWorks Therapeutics by 20.3% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,465 shares of the company's stock valued at $220,000 after acquiring an additional 754 shares during the last quarter. DNB Asset Management AS raised its position in shares of SpringWorks Therapeutics by 16.5% in the second quarter. DNB Asset Management AS now owns 11,402 shares of the company's stock valued at $429,000 after purchasing an additional 1,617 shares during the period. First Horizon Advisors Inc. boosted its holdings in SpringWorks Therapeutics by 47.9% during the second quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company's stock valued at $45,000 after acquiring an additional 383 shares during the period. Bank of New York Mellon Corp increased its stake in shares of SpringWorks Therapeutics by 28.4% in the second quarter. Bank of New York Mellon Corp now owns 298,961 shares of the company's stock worth $11,262,000 after purchasing an additional 66,161 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of SpringWorks Therapeutics during the 2nd quarter worth about $123,000.

SpringWorks Therapeutics Stock Up 1.6 %

SpringWorks Therapeutics stock traded up $0.68 during midday trading on Tuesday, reaching $42.55. The stock had a trading volume of 887,657 shares, compared to its average volume of 1,001,725. SpringWorks Therapeutics, Inc. has a 1-year low of $28.21 and a 1-year high of $53.92. The firm's fifty day simple moving average is $33.19 and its 200-day simple moving average is $36.68.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.03. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The business had revenue of $49.10 million during the quarter, compared to the consensus estimate of $53.28 million. During the same period last year, the business posted ($1.27) EPS. SpringWorks Therapeutics's revenue was up 4810.0% on a year-over-year basis. On average, analysts predict that SpringWorks Therapeutics, Inc. will post -3.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on SWTX shares. Evercore ISI started coverage on SpringWorks Therapeutics in a research report on Wednesday, November 20th. They issued an "outperform" rating and a $60.00 price objective for the company. Wedbush reissued an "outperform" rating and set a $77.00 price target on shares of SpringWorks Therapeutics in a report on Monday, November 18th. JPMorgan Chase & Co. boosted their target price on SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an "overweight" rating in a report on Wednesday, September 4th. Finally, HC Wainwright lowered their target price on SpringWorks Therapeutics from $76.00 to $74.00 and set a "buy" rating for the company in a research note on Tuesday, November 12th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SpringWorks Therapeutics has an average rating of "Buy" and an average price target of $69.50.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.